Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: de llorens r. Br J Cancer. 2012 Apr 10;106(8):1406-14. doi: 10.1038/bjc.2012.103. Br J Cancer. 2012. PMID: 22491422 Free PMC article.
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C, Massaguer Vall-Llovera A, Carrion Salip D, Vazquez-Martin A, Cufí S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA. Oliveras-Ferraros C, et al. Among authors: de llorens r. Invest New Drugs. 2012 Apr;30(2):846-52. doi: 10.1007/s10637-010-9612-2. Epub 2010 Dec 16. Invest New Drugs. 2012. PMID: 21161326
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: de llorens r. Int J Oncol. 2011 Dec;39(6):1455-79. doi: 10.3892/ijo.2011.1155. Epub 2011 Aug 9. Int J Oncol. 2011. PMID: 21833472
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
Oliveras-Ferraros C, Massaguer Vall-Llovera A, Vazquez-Martin A, Salip DC, Queralt B, Cufí S, Martin-Castillo B, Bosch-Barrera J, Brunet J, De Llorens R, Menendez JA. Oliveras-Ferraros C, et al. Among authors: de llorens r. Oncol Rep. 2012 Jun;27(6):1887-92. doi: 10.3892/or.2012.1732. Epub 2012 Mar 15. Oncol Rep. 2012. PMID: 22427198
A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C, Fonge H, Ferrer-Batallé M, Menéndez JA, Massaguer A, De Llorens R, Reilly RM. Panosa C, et al. Among authors: de llorens r. Nucl Med Biol. 2015 Dec;42(12):931-8. doi: 10.1016/j.nucmedbio.2015.08.003. Epub 2015 Aug 19. Nucl Med Biol. 2015. PMID: 26385534
65 results